Clinical Trial Update: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) [Phase 3]

View source ↗

Summary

Phase 3 trial update for rituximab plus lenalidomide in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal zone lymphoma) has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab + Lenalidomide

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2019-08-13